UNSPSC 51172017: Oxazorone

This classification denotes a cholagogue/choleretic agent with the molecular formula C14H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77243B845F. European Medicines Agency schedules oxazorone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09509MIG. The term OXAZORONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25, no. 10 1971, list 11. ).

OXAZORONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxazorone under HS 29349990 and SITC 51579. As of Q4 2014, OXAZORONE remains the US FDA Preferred Term for this commodity. Oxazorone bears US NLM identifiers UMLS ID C2825424 and NCI Concept Code C81043. SMILES: O1CCN(CC1)CC1C2C(OC(=O)C1)CC(O)CC2.

UNSPSC 51172017 Oxazorone is a Commodity code that covers chemical compounds used in pharmaceutical testing and drug screening applications. State and local governments procure oxazorone primarily as a component in immunoassay-based drug testing protocols, where it serves as a reagent or standard in the analytical confirmation of controlled substances and prescription medications. The issuing bodies soliciting under this code include county community supervision and corrections departments overseeing criminal justice substance-abuse monitoring, state health and human services agencies managing pharmacy benefit programs and therapeutic initiatives, and multistate cooperative purchasing alliances aggregating demand across state and local healthcare systems.

Recent activity shows Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026), with an estimated annual testing volume of approximately 25,031 tests requiring immunoassay screening with LC/MS/MS or GC/MS confirmation—direct applications of chemical reagents and testing standards. The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026 to explore direct-to-manufacturer prescription and pharmaceutical programs, signaling state-level interest in streamlined pharmaceutical sourcing. Minnesota's MMCAP (Minnesota Multistate Cooperative Purchasing Alliance) issued RFP S1070000015802 (proposals due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply products through three authorized wholesalers and maintain cGMP and DSCSA compliance. Texas and Minnesota dominate recent activity under this code, with activity concentrated in state criminal justice and health benefit procurement offices and multistate cooperative purchasing vehicles. The code shows moderate state and local engagement tied to correctional drug testing mandates and state pharmacy benefit consolidation efforts.